BiotechTube

ORX142 Tablets

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Excessive Daytime Sleepiness

Conditions

Excessive Daytime Sleepiness

Trial Timeline

Jun 30, 2025 → Jun 15, 2026

NCT ID
NCT07082829

About ORX142 Tablets

ORX142 Tablets is a phase 1 stage product being developed by Centessa Pharmaceuticals for Excessive Daytime Sleepiness. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07082829. Target conditions include Excessive Daytime Sleepiness.

What happened to similar drugs?

2 of 5 similar drugs in Excessive Daytime Sleepiness were approved

Approved (2) Terminated (1) Active (3)
✅Solriamfetol + PlaceboAxsome TherapeuticsApproved
🔄Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
🔄Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
✅Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
🔄Fibrin Sealant Grifols + EVICELGrifolsPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07082829Phase 1Recruiting

Competing Products

8 competing products in Excessive Daytime Sleepiness

See all competitors
ProductCompanyStageHype Score
Placebo + PF-03654746PfizerPhase 2
35
JZP-110Jazz PharmaceuticalsPhase 2
32
Solriamfetol + PlaceboAxsome TherapeuticsApproved
40
Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
32
Fibrin Sealant Grifols + EVICELGrifolsPhase 3
37
VSF-173Vanda PharmaceuticalsPhase 2
25